FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated.
The FDA has approved ibrutinib (Imbruvica) in combination with obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase approved in 2016 as a single-agent, chemotherapy-regimen for patients with CLL.
Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a...
HHS has announced that Gilead will donate its pre-exposure prophylaxis (PrEP) pill Truvada for up to 200,000 people in a multiyear agreement, just a day after the pharma giant announced that a generic version of the pill will come to market a year early. However, some activists are skeptic.
Genomic sequencing at birth has the potential to shift the healthcare system from reactive to preventive and save countless lives in the process, but healthcare systems aren't ready for widespread implementation of these tests, according to a panel discussion at the World Economic Forum Annual Meeting in Davos, Switzerland.
With the introduction of new classes of drugs in recent years, including immunomodulatory drugs and proteasome inhibitors, the multiple myeloma (MM) treatment landscape has shifted and improved rapidly, with response rates increasing from approximately 30% with single agents to approximately 90% with triplet combination regimens for newly diagnosed patients.
Diabetes represents a common comorbidity among patients with chronic obstructive pulmonary disease (COPD) and is associated with an increased risk of death, according to new study findings, which also found that treatment with metformin can mitigate this risk.
The advent of immunotherapy has significantly shifted the treatment paradigm and prognosis for multiple advanced-stage cancers. In cancers like metastatic melanoma and non-small cell lung cancer (NSCLC), the treatment class has greatly improved survival rates. However, not all patients respond to the treatments, highlighting the need for predictive biomarkers to determine which patients will benefit.
While there is an abundance of research validating the efficacy of primary prophylaxis with granulocyte colony-stimulating factors (G-CSF) for reducing the risk of febrile neutropenia, few studies have looked at trends of treatment uptake over time.
Researchers from the United Kingdom may have unlocked the code to removing the barrier protecting tumors from the effects of immunotherapy. While the results are early, if further research proves the approach effective, it could help boost the impact of treatments like chimeric antigen receptor (CAR) T-cell therapy, which to date hasn't had much luck in solid tumors.